A Randomized, Open-label, Dose-escalation to Rash Study to Assess the Effect of Tarceva in Combination With Gemcitabine on Overall Survival in Patients With Metastatic Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2015
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms RACHEL
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 21 May 2012 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
- 21 May 2012 Actual patient number changed from 391 to 467 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History